Oxford Biomedica......the next level !!!!

We are very focussed on our seven products. We do not intend to fund their programmes for the full ten years or more that it takes from concept to marketed product. We spend enough to demonstrate a proof-of-principle for the product - then licence it to a larger company which finances the more expensive later stages of development. Our costs end and the client pays to license the product - plus making milestone payments. So our commercial return begins within the 10 year development period - a standard model in biotech. TroVax is attracting significant interest and we hope to have a co-development partner for it soon and for it to be marketed around 2008/9.”

Alan Kingsman October 2004.